CDMOs Sterling Pharma Solutions and Novasep have both made announcements in the high potency arena in the past week. The former has signed a manufacturing deal with oncology specialist OncoTex, while the latter is expanding its main high potency API (HPAPI) site at Le Mans.

Pharmaceutical CDMO Sterling Pharma Solutions has announced a new strategic partnership with ADC Biotechnology, a specialist in antibody-drug conjugates (ADCs). Both companies are UK-based.

Sterling will make an unspecified but significant investment in ADC Bio with a view to acquiring it in Q1 2021, subject to due diligence. The businesses will then work together to develop an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s in high potency small molecules.

Pharmaceutical CDMO Sterling Pharma Solutions which is based near Newcastle-upon-Tyne, UK, and was formerly owned by Rhodia and Shasun, has acquired Alcami’s facility at Germantown, Wisconsin (pictured). Terms were not disclosed.

Sterling said that this will boost its API development and manufacturing capacity, particularly for complex and hazardous requirements, and including high potency. Germantown has cGMP development, scale-up and manufacturing facilities with specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.